Syncom Formulations India Ltd (SYNCOMF) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Syncom Formulations India Ltd on NSE and BSE, with an AI summary of each filing.
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Intimation · 13 Nov 2026, 5:30 am
SYNCOM FORMULATIONS (INDIA) LIMITED has informed the Exchange about Board Meeting to be held on 13-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 13 Nov 2026, 5:30 am
Syncom Formulations India Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve Pursuant to Regulation ....
Intimation · 13 Nov 2026, 5:30 am
Syncom Formulations Board Meeting Scheduled for 13th Nov'26 to Consider Q2 Results Syncom Formulations (India) Limited has scheduled its Board of Directors meeting for 13th Nov'26. The board will consider and approve the standalone and consolidated unaudited financial results, along with the limited review report by auditors, for the quarter and half-year ended 30th Sep'26. Additionally, the board will review and approve the unaudited statements of assets and liabilities as well as cash flows for the half-year period.
Corporate Announcement regarding approval and payment of final dividend.
Dividend · 02 Oct 2026, 1:22 am
Syncom Formulations Approves Final Dividend of Rs. 0.10 Per Share for FY26 Syncom Formulations (India) Limited announced that shareholders approved a final dividend of Rs. 0.10 (10%) per equity share of face value Rs. 1/- each for FY25-26 at its 38th AGM on 30th Sep'26. The corporate payout applies to 94,00,00,000 equity shares. Eligible beneficiaries were determined based on the record date of 23rd Sep'26, with dividend proceeds to be directly credited to shareholders' registered bank accounts within the mandated timeframe.
Disclosure under reg 30 of SEBI (LODR) reg 2015 read with sub clause 7 of para A of part A of schedule /// change in directorate.
Change in Management · 02 Oct 2026, 1:13 am
Syncom Formulations Approves Key Board Appointments and Re-appointment at 38th AGM Syncom Formulations (India) Limited announced shareholder approval at its 38th AGM on 30th Sep'26 for key leadership changes. Rahul Vijay Bankda was appointed Director and Managing Director effective 12th Aug'26, bringing over 23 years of experience. Rinki Ankit Bankda was appointed Director and Whole-Time Director effective 12th Aug'26. Additionally, shareholders approved the re-appointment of Ruchi Jindal as a Woman Independent Director for a second five-year term effective 28th Jun'27 to 27th Jun'32. None of the appointees are debarred by SEBI.
Outcome of 38th AGM
Annual General Meeting · 02 Oct 2026, 1:01 am
Declaration of Voting result as per regulation 44(3) of SEBI (LODR) regulation 2015.
Annual General Meeting · 02 Oct 2026, 12:58 am
Syncom Formulations Approves All 10 Resolutions at 38th AGM Syncom Formulations (India) Ltd announced that shareholders approved all 10 resolutions at its 38th AGM held on 30th Sep'26. Key approvals include the adoption of FY26 audited financial statements, a 10% dividend payout of Rs. 0.10 per equity share (face value Rs. 1/-), and the re-appointment of director Mr. Ankit Kedarmal Bankda. Shareholders also confirmed the appointment of Mr. Rahul Vijay Bankda as Managing Director, Mrs. Rinki Ankit Bankda as Whole-Time Director, and approved higher remuneration for CFO Mr. Ankur Vijay Bankda.
Declaration of Result of Remote E Voting and E Voting at 38th AGM incompliance with Regulation 44(3) of SEBI (LODR) Regulation, 2015 in relation to 38th AGM of the company held on 30th ....
Annual General Meeting · 02 Oct 2026, 12:51 am
Submission of proceedings of the 38th Annual General Meeting of the Company held on Wednesday, 30th September, 2026 pursuant to Regulation 30(2) read with Part A of Schedule /// of the ....
Annual General Meeting · 30 Sept 2026, 11:23 pm
Intimation under Regulation 30 of SEBI(LODR) Regulation 2015, Voluntary Waiver/Forgoing of Final Dividend by Promoter/Promoter Group.
Dividend · 26 Sept 2026, 7:46 pm
Syncom Formulations Promoters Voluntarily Waive FY26 Final Dividend Entitlement Syncom Formulations (India) Limited announced on 26th Sep'26 that its promoter group has unconditionally waived its entitlement to the proposed FY26 final dividend of ₹0.10 per share (face value ₹1). Out of 94,00,00,000 total outstanding shares, the promoter group holds 47,53,47,599 shares, resulting in a ₹4.75 Cr dividend waiver. Consequently, upon shareholder approval at the upcoming AGM, the company's net dividend payout will be reduced to ₹4.65 Cr across the remaining 46,46,52,401 non-promoter shares, conserving cash without any compensatory benefits to promoters.
We are pleased to inform you that, pursuant to the provision of regulation 42 of SEBI (LODR) regulation, 2015 and section 91 of companies Act, 2013 the "Record Date" has been fixed as Wednesday ....
Dividend · 18 Sept 2026, 5:19 pm
Syncom Formulations Fixes Record Date for FY26 Dividend Syncom Formulations (India) Limited has fixed 23rd Sep'26 as the record date to determine shareholder eligibility for a final dividend of 10% (Rs. 0.10 per equity share of face value Rs. 1) for FY26. The dividend remains subject to shareholder approval at the company's 38th AGM scheduled for 30th Sep'26. Shareholders opting to waive dividend entitlement must submit the required waiver form by 26th Sep'26.
Pursuant to Reg 36(1)(b) of SEBI (LODR) Regulation, 2015, we hereby inform that company has dispatched the letters to shareholders whose email address is not registered with the company / RTA.
Others (Uncategorized) · 08 Sept 2026, 12:36 am
Syncom Formulations Dispatches FY26 Annual Report Access Details and AGM Notice Syncom Formulations (India) Limited has dispatched physical letters containing direct web links to the FY26 Annual Report and 38th AGM Notice to shareholders without registered email addresses, in compliance with Regulation 36(1)(b) of SEBI LODR Regulations. The 38th AGM is scheduled for 30th Sep'26 at 2:00 PM via Video Conferencing/OAVM. Shareholders requiring physical copies may request them via finance@sfil.in, while shareholder record and detail updates are managed through Registrar and Share Transfer Agent, Ankit Consultancy Private Limited.
Submission of Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26 pursuant to regulation 34(2)(f) of SEBI (LODR) Regulations, 2015
Others (Uncategorized) · 08 Sept 2026, 12:22 am
Syncom Formulations Submits FY25-26 Business Responsibility and Sustainability Report Syncom Formulations (India) Limited submitted its standalone Business Responsibility and Sustainability Report for FY25-26 on 7th Sep'26. For FY25-26, the company posted a standalone sales turnover of ₹48,657.28 Lakhs and net worth of ₹40,624.59 Lakhs. Exports contributed ₹39,637.88 Lakhs (82.94% of turnover), while domestic sales stood at ₹8,298.85 Lakhs (17.05%). Accounts payable days increased to 42 days from 30 days in FY24-25. Scope 1 and Scope 2 GHG emissions dropped to 11.86 mg/m³ and 10.25 mg/m³, respectively, with Zero Liquid Discharge operational across plants.
We are pleased to submit herewith a copy of the Notice of the 38th AGM of the company, scheduled to be held on Wednesday, 30th day of September, 2026 at 2:00 P.M. through Video Conferencing ....
Annual General Meeting · 08 Sept 2026, 12:16 am
Submission of 38th Annual Report along with the Notice of Annual General Meeting to be held on Wednesday, 30th September, 2026 through Video Conferencing ('VC')/ Other Audio Visual Means ....
Others (Uncategorized) · 08 Sept 2026, 12:09 am
PURSUANT TO REG 30 SEBI, LODR, WE HEREBY SUBMIT THE PRESS RELEASE ISSUED BY THE COMPANY
Press Release · 13 Aug 2026, 11:22 pm
Syncom Formulations Reports Strong Q1 Profitability Growth Syncom Formulations reported strong Q1 FY27 results, with total income up 8% YoY to ₹133.36 crore. Profitability showed significant improvement, as PBT grew 59% YoY to ₹32.25 crore and PAT increased 58% YoY to ₹24.85 crore. This performance was driven by a 7% YoY rise in revenue from operations to ₹125.53 crore. Consequently, EPS improved to ₹0.26 from ₹0.17. The Board also recommended a final dividend of ₹0.10 per share for FY26, subject to shareholder approval at the upcoming AGM.
Disclosure under Regulation 30(2) read with Clause 7 of Para A of Schedule /// of the SEBI (LODR) Regulation, 2015: Change in directors, KMP and Senior Management.
Change in Management · 12 Aug 2026, 12:48 am
Syncom Formulations Announces Major Leadership and Board Reshuffle Syncom Formulations announced a significant management overhaul effective 11-12 Aug'26. Key changes include the resignations of Managing Director Vijay Bankda, Whole-time Director Kedarmal Bankda, and CFO Rahul Vijay Bankda. Rahul Vijay Bankda was subsequently appointed as the new Managing Director. Ankur Vijay Bankda has been redesignated as the new CFO, and Rinki Ankit Bankda has been appointed as Whole-time Director. The changes are part of a leadership transition and succession plan. Additionally, Ruchi Jindal's reappointment as Woman Independent Director was approved, effective 29 Jun'27.
Corporate Announcement/Information pursuant to Regulation 44 of the SEBI (LODR) Regulation, 2015 regarding providing Remote E-Voting facilities for the 38th Annual General Meeting to be ....
Annual General Meeting · 12 Aug 2026, 12:43 am
Appointment of Cost Auditor and Internal Auditor for the FY 2026-27.
Change in Auditor · 12 Aug 2026, 12:31 am
Syncom Board Approves Cost and Internal Auditor Appointments for FY27 Syncom Formulations announced its Board of Directors, at its meeting on 11 Aug'26, approved key auditor appointments for FY 2026-27. M/s M. Goyal & Co. Cost Accountants (Firm Reg. No. 000051) has been appointed as the Cost Auditor. Additionally, M/s Bansal & Agrawal, Chartered Accountants (Firm Reg. No. 010803C) has been named the Internal Auditor for the same fiscal year. Both appointments were based on the recommendations of the Audit Committee and are effective 12 Aug'26.
Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report thereon ....
Financial Result · 11 Aug 2026, 11:53 pm
Syncom Formulations Reports Strong YoY Profit Growth in Q1 FY27 For Q1 ended 30 Jun'26, Syncom Formulations reported a 57.6% YoY increase in consolidated Net Profit to ₹2,484.68 Lacs from ₹1,575.44 Lacs. Consolidated Revenue from Operations grew 7.4% YoY to ₹12,552.64 Lacs. On a standalone basis, Net Profit rose 56.3% YoY to ₹2,458.92 Lacs. The Pharmaceuticals segment remains the primary driver, contributing ₹13,135.78 Lacs to standalone segment revenue. Basic EPS for the quarter was ₹0.26, up from ₹0.17 in the prior year period, reflecting improved profitability.
We are pleased to inform you that, pursuant to the provision of Regulation 42 of SEBI (LODR) Regulations, 2015 and Section 91 of the Companies Act, 2013 the "Record Date" has been fixed ....
Dividend · 11 Aug 2026, 11:24 pm
Outcome of the 2/2026-27 Meeting of the Board of Directors of the Company held on Tuesday, 11th August 2026 pursuant to Regulation 30 read with Schedule III(A)(IV) of the SEBI(LODR) Regulations, 2015.
Outcome · 11 Aug 2026, 11:16 pm
Syncom Board Approves Q1 Results, Dividend, and Key Leadership Changes Syncom Formulations’ board approved unaudited results for the quarter ended 30th Jun'26 and recommended a final dividend of Rs. 0.10 per share (10%) for FY26, with a record date of 23rd Sep'26. The 38th AGM is scheduled for 30th Sep'26 via video conference. Significant leadership changes were noted, including the resignation of Kedarmal Bankda (Whole-time Director), Vijay Bankda (MD), and Rahul Vijay Bankda (CFO). Rahul Vijay Bankda was subsequently appointed as MD, and Ankur Vijay Bankda as the new CFO.
Revised Intimation for resignation of Mr. Vijay Shankarlal Bankda Managing Director Under Regulation 30 of SEBI (LODR) Regulations, 2015.
Change in Management · 10 Aug 2026, 11:48 pm
Syncom Formulations Managing Director Resigns as Part of Succession Plan Syncom Formulations (India) Ltd. announced the resignation of Mr. Vijay Shankarlal Bankda from his roles as Managing Director and Director, effective 11th Aug'26. The resignation, submitted on 8th Aug'26, is cited as part of a planned leadership transition and effective succession planning. Mr. Bankda, a Founder Promoter, confirmed the decision is voluntary and not due to any disagreement with the Board or management. The company's Board has acknowledged and accepted the resignation.
Intimation for Resignation of Mr. Vijay Shankarlal Bankda Managing Director under Regulation 30 of SEBI (LODR) Regulations, 2015
Change in Management · 08 Aug 2026, 8:30 pm
Syncom Formulations Managing Director Steps Down Mr. Vijay Shankarlal Bankda has resigned as Managing Director and Director of Syncom Formulations (India) Limited. The resignation, tendered on 08 Aug'26, will be effective from the close of business hours on 11 Aug'26. The company filing cited planned leadership transition and succession planning as the reason for his departure. The resignation was confirmed to be voluntary, with no disagreements reported with the board or management.
Intimation for Resignation of Mr. Rahul Vijay Bankda Chief Financial Officer (CFO) under Regulation 30 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015
Change in Management · 08 Aug 2026, 6:49 pm
Syncom Formulations CFO Rahul Vijay Bankda Resigns Syncom Formulations (India) Limited announced the resignation of its Chief Financial Officer (CFO), Mr. Rahul Vijay Bankda, effective from 11th Aug'26. The company received the resignation letter on 08th Aug'26. According to the filing, Mr. Bankda is leaving the CFO role to undertake a different professional responsibility within the organization and confirmed no disagreement with the Board of Directors. The Board acknowledged his contribution and stated that he will remain associated with the company in a different capacity.